Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for approximately 15–20% of all breast cancers, and its prognosis has been improved in the past two decades by new treatments such as trastuzumab, pertuzumab and lapatinib (Loibl and Gianni, 2017). Here, ERBB2 is linked to breast carcinoma.